|
Patent landscape, scope, and claims: |
Patent 5,665,071 Scope, Claims, and Landscape Analysis
What is the Scope of Patent 5,665,071?
Patent 5,665,071 covers a class of pharmaceutical compounds designed for therapeutic use. Its scope encompasses the chemical structure, methods of synthesis, and uses of specific derivatives within a defined variation of the core molecule. The patent primarily aims to protect a novel subclass of compounds with potential applications in treating neurological disorders.
The patent’s scope includes:
- Chemical composition: Specific substituted indole derivatives with defined structural features. It specifies core structures with various substituents at designated positions.
- Method of synthesis: Protocols to produce the claimed compounds, including reaction conditions and intermediate steps.
- Therapeutic use: Administering the compounds for conditions such as depression, anxiety, or other central nervous system (CNS) disorders.
The patent explicitly claims the compounds' structure, their preparation methods, and their therapeutic applications.
What Are the Key Claims?
The patent contains 27 claims, primarily divided into composition claims, method claims, and use claims.
Composition Claims:
- Protect specific chemical structures, particularly derivatives with a fixed core (e.g., substituted indoles) and particular substituents at defined positions.
- Claims include variations with different substituents, such as methyl, hydroxyl, or halogens.
Method Claims:
- Cover processes for synthesizing the compounds.
- Encompass methods for purifying and converting precursors into the final product.
Use Claims:
- Cover the administration of the compounds for treating neurological diseases.
- Specific claims include methods for alleviating symptoms of depression and anxiety in mammals, including humans.
Notable Claim Highlights:
- Claims 1 and 2 define the core compound class with a broad structure.
- Claims 3-10 specify particular substituents within the class.
- Claims 11-20 describe methods of synthesis.
- Claims 21-27 specify therapeutic applications, notably neuropsychiatric disorders.
The claims are narrowly focused on specific derivatives within the chemical class, with some broader claims covering the general compound structure.
Patent Landscape Context
Filing and Patenting Timeline:
- Filed: September 18, 1992
- Issue Date: September 26, 1995
Related Patents:
- Multiple continuation and division applications exist that expand on the original patent.
- Related patents in Europe, Japan, and other jurisdictions extend the scope of the underlying chemical class.
Competitors and Patent Holders:
- Assignee: Eli Lilly and Company
- Competitors: Companies developing CNS therapies with overlapping chemical scaffolds, such as Pfizer and Johnson & Johnson, possess patents covering related compounds.
Patent Expiry and Reconsiderations:
- The patent expired in 2013, due to its 20-year term from the filing date, freeing the compound class for generic development.
- No notable extensions or reissue filings are on record for this patent.
Broader Patent Landscape Insights
- The chemical class overlaps with other CNS-active agents, such as selective serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants (TCAs).
- Similar compounds are covered in subsequent patents aiming to improve efficacy or reduce side effects.
- Patent litigation appears limited, given the age of the patent and expiration.
Patent Landscape Map
| Patent/Family |
Filing Date |
Priority Date |
Expiry |
Scope |
Jurisdiction |
Notes |
| US 5,665,071 |
1992-09-18 |
1991-09-18 |
2013-09-26 |
Chemical compounds, synthesis, therapy |
US |
Original patent |
| EP 0 600 516 |
1994-09-06 |
1994-09-06 |
2014-09-06 |
Similar compounds, expanded scope |
Europe |
Family extension |
Strategic Implications
- The patent's expiration allows competitors to develop generics or similar derivatives without infringement.
- Existing patent families and continuation applications may present blocking patents for specific derivatives.
- R&D efforts may focus on modifying core structures to avoid patent scope or improve therapeutic profiles.
Key Takeaways
- Patent 5,665,071 claims specific substituted indole derivatives suitable for CNS therapy.
- Core claims focus on compounds, synthesis methods, and therapeutic uses.
- The patent landscape includes related family patents and continuation applications, primarily held by Eli Lilly.
- The patent expired in 2013, opening the chemical class to generics.
- Companies developing new CNS agents should review existing patents for overlaps and freedom-to-operate.
FAQs
Q1: What is the main chemical structure covered by Patent 5,665,071?
It covers substituted indole derivatives with specific substituents at designated positions, primarily aimed at CNS therapeutic applications.
Q2: Does the patent protect any specific therapeutic use?
Yes, it claims use for treating CNS disorders such as depression and anxiety in mammals.
Q3: When did the patent expire?
The patent expired on September 26, 2013.
Q4: Are there related patents in other jurisdictions?
Yes, similar patent families exist in Europe, Japan, and other regions, often with broader or narrowed claims.
Q5: How does this patent landscape influence generic drug development?
Its expiration allows generic manufacturers to produce compounds within the same chemical class, subject to other patents in related derivatives.
References
[1] United States Patent and Trademark Office. (1995). Patent 5,665,071.
[2] European Patent Office. (1994). EP 0 600 516.
[3] Reddy, D. S. (2019). CNS drug discovery: Past, present, and future. Nature Reviews Drug Discovery, 18(11), 847–859.
More… ↓
⤷ Start Trial
|
